Over a year ago, a new camera stunned the world with its ability to snap 10 trillion frames per second. That speed made it ...

Results of the Phase I clinical trial, presented at the bi-annual Contrast Media Research symposium in Oslo, Norway, conclude that this novel macrocyclic manganese-based contrast agent was well ...

The investigational MRI contrast agent, gadoquatrane, is designed to deliver effective imaging at a significantly reduced ...

GE HealthCare has announced positive results from a Phase I study of its manganese-based macrocyclic magnetic resonance imaging (MRI) contrast agent. Data from the first-in-human trial ...

This project pioneers ‘Phase Imaging’ that visualizes the phase information of quantum beams (X-rays, neutrons, electrons, and so on) passing through objects. Phase imaging is different from ...

Bayer offers a leading portfolio of contrast media for computed tomography (CT), X-ray, and magnetic resonance imaging (MRI), along with devices for their precise administration, informatics ...

Bayer is on the brink of filing a new MRI contrast agent for approval that can reduce levels of gadolinium, a rare earth metal that can have health and environmental consequences. The company has ...

Barium contrast media plays an essential role in gastrointestinal imaging, offering a reliable, radiopaque medium with favorable safety and cost profiles compared to iodinated agents.

Berlin: Bayer has announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for its investigational contrast agent gadoquatrane for ...

Results of the Phase I clinical trial, presented at the bi-annual Contrast Media Research symposium in Oslo, Norway, conclude that this novel macrocyclic manganese-based contrast agent was well ...

Results of the Phase I clinical trial, presented at the bi-annual Contrast Media Research symposium in Oslo, Norway, conclude that this novel macrocyclic manganese-based contrast agent was well ...